Novel application of adenovirus and nuclear acids encoding it

FIELD: medicine.

SUBSTANCE: claimed invention relates to field of molecular biology, virology and medicine. Claimed is application of adenovirus for manufacturing medication for tumor treatment. Said virus is replication-deficient in cells which do not contain YB-1 in nucleus and encodes oncogenic protein E1A, which transactivates at least one viral gene from group including E1B55kDa, E4orf6, E4orf6 and E3ADP.

EFFECT: invention can be used for treating tumors demonstrating resistance to many cytostatic medications.

19 cl, 19 dwg, 13 ex

 

The text descriptions are given in facsimile form.

. The use of a virus for the manufacture of a medicinal product for the treatment of tumors, wherein the virus is an adenovirus, which is deficient for replication in cells that do not contain YB-1 in the nucleus, where the virus encodes the oncogenic protein EA that transactivity at least one viral gene, where the specified gene selected from the group comprising E1B55kDa, E4orf6, E4orf3 and E3ADP.

2. Use according to claim 1, characterized in that the virus replicates in cells that contain YB-1 in the nucleus.

3. The use according to claim 1, characterized in that said viral oncogenic protein is EA, and/or specified oncogene is a gene that encodes EA, and/or specified oncogenic protein is EA.

4. The use according to claim 3, characterized in that the viral oncoprotein EA does not induce nuclear localization of YB-1.

5. The use according to claim 1, characterized in that these cells are Rb-negative, and such cells are positive for nuclear YB-1, and preferably, these cells are positive for nuclear YB-1 regardless of the cell cycle.

6. The use according to claim 1, characterized in that the cells forming the tumor or its parts, are resistant to pharmacologically effective agents.

7. The use according to claim 6, characterized in that the cell detects the t the overexpression of membrane-bound transport protein P-glycoprotein.

8. The use according to claim 1, characterized in that the viral oncogenic protein is under the control of tissue-specific and/or tumor-specific promoter.

9. The use according to claim 1, characterized in that the virus encodes YB-1.

10. The use according to claim 9, characterized in that the YB-1 is under the control of tissue-specific and/or tumor-specific promoter.

11. The use according to claim 1, characterized in that the virus encodes at least one protein selected from the group comprising E4orf6, E4orf3, E1B55kDa and adenoviral protein E3ADP.

12. The use according to claim 1, characterized in that the cells forming the tumor or part of it, contain YB-1 in the nucleus.

13. The use according to claim 1, characterized in that the tumor contain YB-1 in the cell nucleus after induction of the transport of YB-1 into the kernel.

14. The use according to claim 1, wherein the virus is selected from the group comprising AdΔ24, dl922-947, E1Δd/01/07, d11119/1131, CB016, dl520 and viruses, which expressed viral oncogene unable to contact a functional gene product is a tumor suppressor, Rb.

15. The use of a nucleic acid that encodes the virus used according to any one of claims 1 to 14 for the manufacture of a medicinal product, and preferably, for manufacturing a medicinal product for the treatment of tumors.

16. Use the .15, characterized in that the cells forming the tumor or its parts, are resistant to pharmacologically effective agents.

17. The application of clause 16, wherein the specified resistance is polyresistance.

18. The application of item 16 or 17, characterized in that said pharmacologically active agent is an anticancer agent.

19. Use p, characterized in that said anti-tumor agent is a cytotoxic agent.
Priority items:

27.05.2002 according to claim 2 - 19;

19.05.2003 according to claim 1.



 

Same patents:

FIELD: chemistry, pharmaceutics.

SUBSTANCE: claimed invention relates to method of acidifying of one or several amino groups of peptide which is selected from group including exendin-3, exendin-4, Arg34-GLP-1(7-37), Gly8-GLP-1(7-36)-amide, Gly8-GLP-1(7-37), Val8-GLP-1(7-36)-amide, Val8-GLP-1(7-37), Val8Asp22-GLP-1(7-36)-amide, Val8Asp22-GLP-1(7-37), Val8Glu22-GLP-1(7-36)-amide, Val8Glu22-GLP-1(7-37), Val8Lys22-GLP-1(7-36)-amide, Val8Lys22-GLP-1(7-37), Val8Arg22-GLP-1(7-36)-amide, Val8Arg22-GLP-1(7-37), Val8His22-GLP-1(7-36)-amide, Val8His22-GLP-1(7-37), des(B30)-human insulin and their analogues, in which reaction of acidifying is carried out in water mixture containing less than 10% wt/wt aprotonic polar solvent, and interaction of peptide with acidifying agent of general formula I is carried out, where n is 0-8; R1 represents COOR4; R2 represents lipophilic part of molecule; R3 together with carboxyl group, to which R3 is bound, represents reaction-able ester or reaction-able N-hydroxyimidoesther; and R4 is selected from group including hydrogen, C1-12-alkyl and benzyl; in base conditions in water solution, acidifying agent being added to reaction mixture in form of solution stabilised by adding acid.

EFFECT: obtaining efficient method of peptide acidifying.

17 cl, 2 tbl, 8 ex

FIELD: chemistry, biochemistry.

SUBSTANCE: invention refers to biochemistry and can be used in pharmaceutical industry for mixture purification of natural mixtures containing plasminogen and fibrinogen from plasminogen. Plasminogen is removed from mixture containing plasminogen and fibrinogen using insoluble chromatography matrix that is covalently cross-linked with tranexamic acid through amino group with linker of length exceeding three carbon atoms. Therefore mixture mentioned above is applied on chromatographic column containing specified insoluble matrix. Then column is washed with neutral solution containing salts, while unbound material is collected.

EFFECT: extended technical feasibilities of purification of natural mixtures containing plasminogen and fibrinogen from plasminogen thus keeping original amount of fibrinogen in mixture.

15 cl, 1 dwg, 13 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: method of obtaining dodecapeptide of the formula I: H-Asp-His-Leu-Asp-Lys-Gln-Thr-Gln-Thr-Pro-Lys-Thr-OH and tripeptide of the formula II: X-Asp(Y)-His-Leu-OH is the intermediate compound in its synthesis. Solid-phase synthesis of dodecapeptide I is realised by sequential growth of the peptide chain, beginning with the C-end dipeptidilpolymertill the obtaining of C-end nonapeptidilpolimer, which is condensed with the protected N-end tripeptide of the formula II: X-Asp (Y)-His-Leu-OH where X, Y are protected groups and the obtained dodecapeptidilpolymer is processed with an unblocking agent for removing the protective groups and the polymeric matrix and in 1 stage the end product is given out by means of HELC.

EFFECT: increasing the output of the end product and simplification of the process.

3 cl, 2 ex

FIELD: chemistry.

SUBSTANCE: sunflower seeds are crushed, de-oiled, extracted and separated into phases of centrifugal process. Double precipitation of the obtained lipoprotein complex with an acid at an isoelectric point at a pH=4.6-4.8, processing using an alkaline solution, washing of the fixed residue using water and drying. Extraction of the fat extracted residue is conducted using a trisglycinate buffer at a ratio seeds: buffer 1:16.7, and then held for two hours. Centrifugal process is carried out at 8000 rev/min for 15 minutes, and precipitated 0.1 n amber acid solution. Drying is carried out till a residual humidity of 6-8%.

EFFECT: increase in the protein content, less toxicity while reducing the time interval.

4 cl, 1 tbl, 1 dwg, 4 ex

FIELD: chemistry.

SUBSTANCE: sunflower seeds are crushed, de-oiled, extracted and separated into phases of centrifugal process. Double precipitation of the obtained lipoprotein complex with an acid at an isoelectric point at a pH=4.6-4.8, processing using an alkaline solution, washing of the fixed residue using water and drying. Extraction of the fat extracted residue is conducted using a trisglycinate buffer at a ratio seeds: buffer 1:16.7, and then held for two hours. Centrifugal process is carried out at 8000 rev/min for 15 minutes, and precipitated 0.1 n amber acid solution. Drying is carried out till a residual humidity of 6-8%.

EFFECT: increase in the protein content, less toxicity while reducing the time interval.

4 cl, 1 tbl, 1 dwg, 4 ex

FIELD: biology, biotechnologies.

SUBSTANCE: invention can be used in the food-processing industry. For obtaining of 6-O-αD-(1,6-GPS) isomaltulose would submit to the reactionary solution containing enzyme, possessing ability of catalyzing transformation of isomaltulose in 1,6-GPS from which allocate a target product after an incubation at temperature of 20-40°C. Before or during incubation in a reactionary solution add regenerative equivalents. Allocate enzyme with means of anion exchange and two affine chromatography from a crude extract of a microorganism of sort Gluconobacter containing a gene of enzyme, possessing ability of catalyzing transformation of isomaltulose in 1,6-GPS. The nucleic acid coding enzyme, possessing ability to catalyze transformation of isomaltulose in 1,6-GPS is obtained. The vector containing given nucleic acid, is intended for provision of an expression of this enzyme in a host cell.

EFFECT: invention application allows obtaining 6-O-αD-D-D-sorbite from isomaltulose by means of the unique enzymatic reaction.

26 cl, 2 dwg, 1 tbl, 4 ex

FIELD: chemistry, biotechnology.

SUBSTANCE: invention relates to field of biotechnology and preparation chemistry and can be used in biopharmacology and medicine. Cells of yeast P.pastoris are successively transformed by two different genetic structures, containing gene of human serum albumin (HAS) precursor. Obtained strain-producent is cultivated in nutrient medium. Recombinant HAS is isolated from cultural medium by clarification of said medium, as well as carrying out stages of successive centrifuging at 2000 and 10000 g, ultrafiltration, dialysis and cation-exchanging chromatography on column Source S. Target product represents eluate, including recombinant human serum albumin, 50 mM phosphate buffer, containing 400 mM of sodium chloride, with pH 9. Application of said iclaimed invention allows to extend arsenal of means, directed at production of recombinant HAS, and to obtain recombinant HAS in form of product, which in addition to recombinant HAS contains 50 mM phosphate buffer, containing 400 mM of sodium chloride and has pH 9.

EFFECT: extension of arsenal of means directed at obtaining recombinant HAS.

2 cl, 7 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology. Method versions lie in fact that trisulfide isoform is brought into contact with mercaptocompound, either with chelating agent or with metal salt.

EFFECT: obtaining polypeptide product with reduced amount of trisulfide isoform admixtures.

30 cl, 5 dwg, 7 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology. Method versions lie in fact that trisulfide isoform is brought into contact with mercaptocompound, either with chelating agent or with metal salt.

EFFECT: obtaining polypeptide product with reduced amount of trisulfide isoform admixtures.

30 cl, 5 dwg, 7 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology. The method of thymic peptide prodaction involves fining of product of mammals' immunotropic tissue containing peptides with thymic activity, homogenisation, centrifugation and filtration with refining and segregating of the final product. Three times freezing and thawing of the tissue in the mixture with distilled water are carried out before homogenisation. Hereafter, centrifugation of the mixture and filtration of supernatant fluid with deriving filtrate which is precipitated by 0,1-0,6M sulphosalicylic acid, than protein fraction with relative molecular mass less than 10 kDa is segregated from the filtrate. Supernatant fluid is segregated with 0,33% phosphorno-wolframic acid, aging within 60 minutes, centrifuged and precipitation, which is suspended in distilled water is separated. Hereafter, the sediment is dissolved by adding saturated alkaline solution with up to 9,0 pH, the final solution is dialysed, defecated by centrifuging and supernatant fluid is separated. Centrifugation is carried out at 8000 rpm during 30 minutes, supernatant fluid is exposed to absorption chromatography on basis of hyrdoxylapatite in water system, notably, and protein fraction, which is not absorbed on a column is concentrated. The protein fraction is exposed to gel filtration, and it's selected with molecular mass less than 10 kDa.

EFFECT: production of thymic peptide with high specific activity and pureness.

3 cl, 6 ex

FIELD: medicine; biotechnologies.

SUBSTANCE: substance of invention involved reconstructed virus membrane with lipid bilayer containing fused virus protein and amphiphilic adjuvant represented with lipopeptide. Further invention refers to production procedures of reconstructed virus membranes manifesting fused membrane activity, that are lipid bilayer membranes preferably containing natural virus lipids, fused virus protein, optionally, one or more additional antigens and amphiphilic adjuvants. Besides invention refers to pharmaceutical compositions containing these reconstructed virus membranes.

EFFECT: intensified immune response.

13 cl, 6 ex, 1 tbl, 10 dwg

FIELD: medicine; virology.

SUBSTANCE: strain expresses the VP2 protein which contacts a monoclonal antibody moab B69 and moab 67, cosecreted by the monoclonal antibody cellular lines HB-9437 and HB-11122. Contains a mutation of coding area of the classical VP2 in the position 222, coding series or threonine, and the nucleotide sequence coding amino-acid sequence, presented in any of SEQ ID No. 1-5 in position 318-323.

EFFECT: effective utilisation for bacterination against infectious bursal disease.

24 cl, 1 dwg, 5 tbl, 2 ex

FIELD: chemistry, pharmaceutics.

SUBSTANCE: invention relates to immunology and biotechnology. Described is polypeptide of protein P17 of HIV virus with amino acid sequence, consisting of peptide, corresponding to neutralising epitope of protein p17 of HIV, and peptide, corresponding to positions 23-32 of protein p17 of HIV. Peptide is bound to peptide of neutralising in carboxy-terminal position of epitope and makes it soluble. Described are vaccine compositions based on polypeptide, versions of polypeptide application such as, for preparation of medication against HIV, and as specific reagent in test on detecting neutralising anti-p-17-antibodies. Described are monoclonal and polyclonal anti-p 17-antibodies, able to recognise neutralising polypeptide epitope in specific way and neutralise its biological activity. Described is application of said antibodies to polypeptide for detecting p17 in biological material and for preparation of medication inhibiting p17 protein activity in HIV-infected people. Application of invention allows to induce neutralising anti- p17-antibodies and inhibit p17 activity which can be applied in medicine for preparation of vaccine of injection material against HIV.

EFFECT: obtaining composition which can be applied in medicine for preparation of vaccine or injection material against HIV.

17 cl, 9 ex

FIELD: medicine; gastroenterology.

SUBSTANCE: antibacterial therapy is presented with selective decontamination using antiklebsiellic bacteriophage within 10 days. After that prebiotic therapy including Hylak Forte, enzymatic agent and Linex in therapeutic dosage is combined with probiotic introduction. For dysbacteriosis of I stage Bifiform is introduced in dose 1 capsule 2 times a day, for dysbacteriosis of II and III stages dose is 2 capsules 2 times a day, combined with Lactobacterinum 5 doses once a day. Thus medicinal plant tincture is introduced including silverweed rootstock, salvia leaves, milfoil herb, St. John's wort herb, elecampane rootstock with roots, tickseed herb, mint leaves, fennel fruits and buckthorn bark at component ratio respectively 2:2:2:2:2:2:2:2:1 dosed 1\3 of glass 3 times a day, 30 min before meal, within 4 weeks.

EFFECT: method has no contraindications and provides fast normalisation of gastrointestinal tract microflora.

1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention concerns virology and biotechnology area. The way provides introduction of the vaccine chosen from a group, consisting (a) from modified live vaccine BVDV of type 1, (b) from modified live vaccine BVDV of type 2, and (c) simultaneously from modified live vaccine BVDV of type 1 and modified live vaccine BVDV of type 2 to an animal. The invention is effective for prevention or depression of an infection of the spermaries caused by infection BVDV of type 1 and 2. The invention can be used in veterinary science and animal industries.

EFFECT: prevention or depression of an infection of the spermaries caused by infection BVDV.

20 cl, 1 dwg, 4 tbl, 2 ex

FIELD: biotechnologies.

SUBSTANCE: invention claims a vector including one, two or more pgsB, pgsC and pgsA genes encoding poly-gamma-glutamine acid synthase complex, and a gene encoding spike antigen albumen or antigen albumen of SARS coronavirus nucleocapsid. The gene encoding spike or SARS coronavirus nucleocapsid antigen albumen is linked to the C-end part of one, two or more pgsB, pgsC and pgsA genes. The vector enables albumen expression at a cell surface. Also the invention claims a microbe transformed by such vector enabling albumen expression at a cell surface, and a SARS preventing vaccine containing such microbe. The vaccine for SARS prevention and treatment, using recombinant strain expressing SARS coronavirus antigen over its surface, is efficient and cost-effective.

EFFECT: vector enabling albumen expression at a cell surface.

19 cl, 18 dwg, 9 ex

FIELD: medicine; pediatrics.

SUBSTANCE: by the first vaccination of 3-18 months old children vaccination is performed at least over 60 days after their arrival to Far North regions from other climatic zones.

EFFECT: high vaccination efficiency due to taking in consideration processes of child organism adaptation to a change of climatic zones.

7 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to delivery system for antigen as T-cell, containing, at least, one antigen and loading antigen-presenting cells with specified antigen. Application of T-cell containing at least one antigen is offered in medical product for antigen delivery to lymph node. Application of antigen associated with T-cell containing at least one other antigen causing immune response is offered in medical product for immune response monitoring against at least one other antigen. Application of T-cell containing at least one antigen is offered in medical product for antigen-presenting cells (APC) loading with antigen.

EFFECT: offered method of T-cell production for application under any item mentioned above, including T-cell isolation, T-cell activation, T-cell cultivation and antigen introduction to T-cell, where T-cell is transduced with antigen.

24 cl, 8 ex, 1 tbl, 7 dwg

FIELD: medicine; pharmacology.

SUBSTANCE: invention relates to the composition containing the virus-like particle AP205 (VLP) and antigen. The invention also relates to the method of production of the antigen or antigen determinant, bound to VLP AP205. Antigen- bound VLP AP205 are used for production of compositions for immune response induction. The compositions are used in prevention or treatment of diseases, abnormalities or conditions, including infectious diseases, allergy, cancer, drug abuse, intoxications.

EFFECT: invention is used for efficient induction of auto-specific immune responses.

43 cl, 15 dwg, 1 tbl, 13 ex1

FIELD: medicine, virology, immunology, molecular biology.

SUBSTANCE: invention proposes a composition containing virus-like particle and at least one protein or peptide IL-5, IL-13 or human eotaxine bound with its. Also, invention discloses method for preparing this composition and using, pharmaceutical composition and vaccine composition containing such composition. Proposed compositions can be used in treatment of allergic diseases with an eosinophilic component. Except for, proposed compositions are used especially for effective induction of responses specific for autoantigens.

EFFECT: valuable medicinal properties of composition.

40 cl, 1 tbl, 14 dwg, 11 ex

FIELD: biotechnology, veterinary science.

SUBSTANCE: invention relates to therapeutic vector used in therapy of infectious diseases in cats that comprises at least one foreign nucleic acid each of that (a) encodes protein taken among the group consisting of feline protein CD28 represented in SEQ ID NO:8 or its immunogenic moiety; feline protein CD80 represented in SEQ ID NO:2 or 3, or its immunogenic moiety; feline protein CD86 represented in SEQ ID NO:6 or its immunogenic moiety, or feline protein CTLA-4 represented in SEQ ID NO:10 or its immunogenic moiety; and (b) nucleic acid that is able to be expressed in insertion of vector in the corresponding host. Indicated therapeutic vector is used in effective dose as component of vaccine against infectious diseases in cats for their immunization and in methods for enhancement or inhibition of immune response in cats and reducing or eradication of tumor in cats. Invention provides stimulating the activation and proliferation of T cells and to enhance effectiveness of control of infectious diseases in cats.

EFFECT: valuable biological properties of recombinant virus.

41 cl, 13 dwg

Up!